TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07896590: A Randomized, Multicenter, Open Label Phase 3 Study to Evaluate Orelabrutinib Combined With ICP 248 Versus Orelabrutinib Monotherapy for Relapsed/Refractory Marginal Zone Lymphoma

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 292 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,498,484

Rescue Site Savings

+$9,578,184

Unlock Full NCT07896590 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07896590 Rescue Dossier →